Vivos Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Vivos Therapeutics

14/08/2026 12:03

Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to  show a rise in quarterly revenue when it reports  results on August 17 (estimated) for the period ending June 30 2026
The Littleton Colorado-based  company is expected to report a 40.5% increase in revenue to $5.367 million from $3.82 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 39 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Vivos Therapeutics Inc is $2.50, about 718.9% above its last closing price of $0.31
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.44
-0.45
-0.52
Missed
-14.7
Dec. 31 2026
-0.46
-0.48
-0.58
Missed
-20
Sep. 30 2025
-0.52
-0.51
-0.49
Beat
3.9​
Jun. 30 2025
-0.38
-0.38
-0.55
Missed
-42.9
​​Mar. 31 2025
-0.40
-0.40
-0.45
Missed
-12.5
Dec. 31 2024
-0.39
-0.28
Beat
29.1​
Sep. 30 2024
-0.61
-0.61
-0.40
Beat
34.4
Jun. 30 2024
-1.05
-0.60
Beat
42.9
This summary was machine generated August 14 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)